News – Page 428 – Endpoints News

German biotech CatalYm raises $50M to flip weight loss target for cancer

3 years ago

Prothena nets more cash from Novo Nordisk; Khondrion fails to hit endpoint

3 years ago

Biden forges new $475M campaign to drive uptake of Pfizer and Moderna's bivalent Covid vaccines

3 years ago

Surprise data drop by conference puts Arvinas in cleanup mode

3 years ago

ObsEva, desperate for cash, sells rights to PhII drug in bid to extend runway, test new pregnancy candidate

3 years ago

Cyclerion board quickly nixes CEO Peter Hecht's unorthodox pitch for low cash reserves

3 years ago

Simulations for experiments: Bayer-backed startup lands $20M to test out its tech

3 years ago

Days after reporting PhIII failure, GSK pulls BCMA drug from US market — but it's not giving up entirely yet

3 years ago

After Chinese CDMO fails, Cambrex acquires ingredient manufacturer Snapdragon Chemistry

3 years ago

Eli Lilly to double its manufacturing capacity for Mounjaro as it faces financial headwinds going into 2023 — ...

3 years ago

Takeda goes back to school, teaming up with Discovery Education for health equity initiative

3 years ago

Biggest drug companies halted Twitter ad buys after Lilly insulin spoof

3 years ago

Court KOs REMS-related patent listing for Jazz narcolepsy drug

3 years ago

Anti-abortion groups file suit against FDA in Texas, demands agency revoke approval for abortion pill

3 years ago

Maker of new gene therapy vector launches its second company, looking to zero in on rare skin conditions

3 years ago

Six-person ALS biotech wants to go public — but it’s also pivoting from earlier plans

3 years ago

With the clinic in sight, Greg Verdine's startup bags $178M for new class of targeted therapies

3 years ago

Rare in common: Health Union's newest social community aims to connect across rare diseases

3 years ago

Merck KGaA spotlights need for deals to shake up R&D, with external partners key to new drugs

3 years ago

Plexxikon vets kick off new drug discovery outfit — with old assets and new target

3 years ago

Updated: Teva picks former Sandoz head as new CEO to replace Kåre Schultz

3 years ago

Updated: No Seagen here: 'Do more' means a small $1.35B purchase of Imago for Merck

3 years ago

Gene therapy flunks PhII/III study, but former Sarepta partner sees a path forward — if it can find the cash

3 years ago

Alzheimer’s drug bites the dust; Restructure, restructure, restructure; Landmark diabetes OK; and more

3 years ago

First page Previous page 425 426 427428429 430 431 Next page Last page